Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
10-K
2023 FY
Annual report
26 Feb 24
8-K
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
26 Feb 24
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
FibroGen Reports Third Quarter 2023 Financial Results
6 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
27 Oct 23
8-K
Departure of Directors or Certain Officers
5 Oct 23
8-K
Departure of Directors or Certain Officers
6 Sep 23
8-K
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
29 Aug 23
S-8
Registration of securities for employees
7 Aug 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
8-K
FibroGen Reports Second Quarter 2023 Financial Results
7 Aug 23
8-K
FibroGen Announces Leadership Transition
25 Jul 23
8-K
Cost Associated with Exit or Disposal Activities
19 Jul 23
8-K
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
26 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
8-K
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
7 Jun 23
DEFA14A
Additional proxy soliciting materials
31 May 23
8-K
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
18 May 23
10-Q
2023 Q1
Quarterly report
8 May 23
8-K
FibroGen Reports First Quarter 2023 Financial Results
8 May 23
8-K
Entry into a Material Definitive Agreement
1 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
424B5
Prospectus supplement for primary offering
27 Feb 23
10-K
2022 FY
Annual report
27 Feb 23
8-K
FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results
27 Feb 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
8-K
FibroGen Reports Third Quarter 2022 Financial Results
7 Nov 22
S-8
Registration of securities for employees
8 Aug 22
S-3ASR
Automatic shelf registration
8 Aug 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
8-K
FibroGen Reports Second Quarter 2022 Financial Results
8 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
17 Jun 22
8-K
Departure of Directors or Certain Officers
8 Jun 22
10-Q
2022 Q1
Quarterly report
9 May 22
8-K
FibroGen Reports First Quarter 2022 Financial Results
9 May 22
Latest ownership filings
3
Deyaa Adib
24 Apr 24
4
Thane Wettig
25 Mar 24
4
Thane Wettig
11 Mar 24
4
Juan Graham
8 Mar 24
4
Thane Wettig
8 Mar 24
4
Christine Chung
8 Mar 24
4
Thane Wettig
23 Feb 24
4
Christine Chung
23 Feb 24
4
Juan Graham
23 Feb 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
PRIMECAP MANAGEMENT CO/CA/
12 Feb 24
4
Thane Wettig
5 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
4
Thane Wettig
26 Dec 23
4
Juan Graham
11 Dec 23
4
Christine Chung
11 Dec 23
4
Thane Wettig
11 Dec 23
4
Thane Wettig
3 Nov 23
4
Thane Wettig
25 Sep 23
4
Juan Graham
8 Sep 23
4
Thane Wettig
8 Sep 23
4
Mark Eisner
8 Sep 23
4
Christine Chung
8 Sep 23
4
Mark Eisner
6 Sep 23
4
Jeffrey William Henderson
6 Sep 23
4
Juan Graham
1 Sep 23
4
Christine Chung
1 Sep 23
144
Notice of proposed sale of securities
1 Sep 23
4
James A Schoeneck
14 Aug 23
4
Thane Wettig
9 Aug 23
4
Jeffrey William Henderson
8 Aug 23
144
Notice of proposed sale of securities
4 Aug 23
SC 13G
MILLENNIUM MANAGEMENT LLC
19 Jul 23
4
Jeffrey William Henderson
13 Jul 23
144
Notice of proposed sale of securities
11 Jul 23
4
Enrique A Conterno
10 Jul 23
4
Thane Wettig
26 Jun 23
144
Notice of proposed sale of securities
23 Jun 23